(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 5.33% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Gilead Sciences's revenue in 2026 is $29,736,000,000.On average, 32 Wall Street analysts forecast GILD's revenue for 2026 to be $38,556,952,437,070, with the lowest GILD revenue forecast at $36,571,682,208,544, and the highest GILD revenue forecast at $40,440,413,935,928. On average, 31 Wall Street analysts forecast GILD's revenue for 2027 to be $40,855,098,273,844, with the lowest GILD revenue forecast at $37,788,420,685,064, and the highest GILD revenue forecast at $43,887,011,906,152.
In 2028, GILD is forecast to generate $43,137,103,702,256 in revenue, with the lowest revenue forecast at $39,188,911,502,936 and the highest revenue forecast at $49,383,441,738,350.